Nattopharma   Report issue

For profit Phase 2
Founded: Oslo Norway (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2013
NCT01972113
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Nattopharma ASA

Active Ingredients

Drugs in Phase 2 Trials (2)

menaquinone (vitamin k2) (4 trials)

vitamin d3 (1 trial)

Drugs in Other Trials (1)

vitamin k2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Calcinosis (Phase 2)

Diabetes Mellitus (Phase 2)

Dyslipidemias (Phase 2)

Glucose Intolerance (Phase 2)

Hypersensitivity (Phase 2)

Insulin Resistance (Phase 2)

Prediabetic State (Phase 2)

Vascular Calcification (Phase 2)

Vitamin K Deficiency (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3